Kiniksa Pharmaceuticals International, plc expects a KPL387 Phase three readout in the second half of 2027 and guides 2026 revenue to 1.045 to $1.050 billion.
KNSA · Kiniksa Pharmaceuticals International, plc
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Price & Indicators
Key stats
- Short volume, last session
- 59%
- Last earnings
- Oct 27, 2026
- Latest filing
- 10-Q · Oct 27
- Price history
- Jan 2020 to Nov 2026
Up next
Latest documents
ARCALYST product revenue, net, reached $286.0 million in the quarter ended September 30, 2026, up $105.1 million from $180.9 million, driven mainly by more patients on therapy. Net income for the nine months ended September 30, 2026 was $95.4 million, versus $44.8 million. Quarterly research and development expenses rose to $32.8 million, led by KPL-387 trial costs of $17.3 million.
Kinexa reported third-quarter ARKLIST revenue of $286 million, up 58% year over year, and raised its 2026 ARKLIST sales guidance to $1.045 to $1.050 billion. It expects pivotal data for KPL 387 in the second half of 2027 and ended the quarter with $568.8 million in cash.
Kiniksa reported third-quarter 2026 revenue of $286.0 million, up from $180.9 million a year earlier, and net income of $47.3 million versus $18.4 million. It raised its 2026 ARCALYST net product revenue expectation to $1.045 billion to $1.050 billion, from $980 million to $995 million. The company ended September 30, 2026 with $568.8 million in cash, cash equivalents and short-term investments and no debt.
Kiniksa appointed Ross Moat as President and Chief Operating Officer, effective immediately, with reporting to Chairman and CEO Sanj K. Patel. Effective January 1, 2027, his annual base salary rises to $700,000 from $650,000 and his annual target bonus to 60% from 55%.
Metrics snapshot
Useful current figures from the complete screener profile.
Quarterly results
* Q4 derived as the full year minus Q1 to Q3.
AI Brief
Q3 FY26 earnings call · Oct 27, 2026TL;DR. ARCALYST revenue grew 58% to $286.0 million, full-year guidance was raised to $1.045-$1.050 billion, and penetration, prescribing, profitability, cash generation, digital engagement, and pipeline development advanced. Operating expenses increased, and KPL-387 efficacy remains to be demonstrated in its ongoing Phase 3 trial.
- + ARCALYST Q3 revenue grew approximately 58% year over year to $286.0 million. new
- + Full-year ARCALYST revenue guidance was raised to $1.045-$1.050 billion from $980-$995 million. new
- + Operating income rose to $54.2 million and net income increased to $47.3 million from $18.4 million. new
- − R&D expense increased to $32.8 million from $24.2 million, primarily due to increased KPL-387 clinical activity. new
- − SG&A expense increased to $65.4 million from $49.1 million, primarily due to ARCALYST commercialization investment. new
- − KPL-387 efficacy remains to be demonstrated in the ongoing Phase 3 pivotal trial. new
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Still-open targets the latest release did not restate under the same label.
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders BuyIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Drug Manufacturers - Specialty & Generic — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
KNSA
this stock
Kiniksa Pharmaceuticals International, plc
|
$7.38B | +127.6% | +60.1% | 71.7 | 5.5% |
|
TAK
Takeda Pharmaceutical Co Ltd
|
$69.55B | +39.6% | — | — | 0.1% |
|
GALDY
Galderma Group AG
|
$50.29B | +4.1% | — | — | 0.0% |
|
TEVA
Teva Pharmaceutical Industries Ltd
|
$45.77B | +25.7% | +4.3% | 89.2 | 2.4% |
|
JHPCY
Jiangsu Hengrui Pharmaceuticals Co., Ltd.
|
$40.66B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every section- Filed
- Nov 16, 2026
- This year
- 22
Kiniksa Pharmaceuticals International, plc expects a KPL387 Phase three readout in the second half of 2027 and guides 2026 revenue to 1.045 to $1.050 billion.
ViewPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| KNSA | -2.5% | +22.4% | +100.1% | +1.8% | +127.6% |
| SPY | -8.6% | -9.2% | -9.2% | -8.7% | +1.2% |
| vs SPY | +6.0% | +31.6% | +109.3% | +10.5% | +126.5% |